NAD+
Nicotinamide adenine dinucleotide
NAD+ (nicotinamide adenine dinucleotide) is one of the most fundamental molecules in your biology — a coenzyme every cell uses for energy production and cellular repair. NAD+ levels fall with age, which is why it sits at the center of the longevity conversation. This guide covers what NAD+ does, how boosting it works, what the research actually shows, the different ways it's used (IV, injectable, oral precursors), dosing references, safety and status.
NAD+ quick facts
| Reported research dosing (Injectable) | 25mg-200mg |
| Route | Either |
| Cycle length | As Long As Needed |
| Frequency | 2-4x Week or Daily |
| Half-life | <1 min (IV); hours as precursor metabolites |
| Forms | Injectable, Nasal |
| Evidence level | Mixed human; strong interest |
| Other forms available | Nasal, Oral — dosed differently |
Go LOW and SLOW — the discomfort people complain about is dosing too fast, every time.
What NAD+ does & how boosting it works
NAD+ is a coenzyme central to cellular energy (it shuttles electrons in the reactions that make ATP) and it's the required fuel for two important enzyme families: the sirtuins (which regulate metabolism, stress resistance and the communication between the nucleus and mitochondria) and PARPs (which repair DNA). The core longevity idea is simple: NAD+ declines with age, sirtuin and repair activity fall with it, and restoring NAD+ — directly or via precursors — reactivates those pathways, improving mitochondrial function and genomic stability in research models.
What the research shows
In model organisms (fruit flies, nematodes, mice), NAD+ or NAD+-precursor supplementation has increased lifespan and promoted healthier aging, with higher NAD+ activating sirtuins and DNA repair. Human research is progressing — precursors like NMN and NR have shown they can raise NAD+ levels and, in some trials, improve markers like aerobic capacity — but the big 'does it extend human healthspan' question is still being answered. It's a foundational, well-studied molecule with promising but still-maturing human outcome data.
The ways NAD+ is used — IV, injection & oral precursors
There are several routes. Oral precursors (NMN, NR) are the convenient, most-studied consumer route — the body converts them to NAD+. IV NAD+ is offered in wellness clinics, delivering large amounts directly to the bloodstream over a few hours. Subcutaneous NAD+ injection is used as a faster, at-home-style alternative to IV. Direct NAD+ (IV/injection) tends to produce more acute side effects than oral precursors, which is why it's typically done under supervision.
NAD+ dosing (research reference)
Referenced ranges vary widely by route. IV NAD+ is commonly cited around 500–1,500 mg per session, spaced weekly to monthly; clinics also reference 250–1,250 mg/day across multi-day protocols. Subcutaneous use references smaller per-dose amounts reconstituted with bacteriostatic water — the calculator above converts a research amount into syringe units. Oral NMN/NR is dosed in hundreds of mg to ~1 g daily in trials. These summarize existing references for education only; IV or injectable use should be medically supervised.
Safety & side effects
Oral NAD+ precursors are generally very well tolerated in trials. Direct IV/injectable NAD+ more commonly causes acute effects — chest tightness, flushing, headache, nausea — especially if infused quickly, which is why it's administered under medical supervision. As with anything affecting metabolism and DNA-repair pathways, this is educational information, not medical advice.
Related compounds
NAD+ is closely tied to MOTS-c and other metabolic/longevity tools, and oral precursors NMN and NR are the practical way many people target the same pathway without injections.
Legal & regulatory status
NAD+ and its precursors are widely available (NMN/NR are sold as supplements), but injectable/IV NAD+ is not FDA-approved as an anti-aging therapy and is offered off-label in wellness settings. Follow the laws and medical guidance that apply to you.
Where to get NAD+
NAD+ is sold in 3 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
NAD+ reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for NAD+
Graded by what exists behind each claim.
✅ Clinically validated
- Human trials exist for the precursors — NR and NMN — and are modest: they reliably raise blood NAD+, and translating that into a clinical endpoint has been much harder. Direct IV NAD+ has small studies and no adequately powered randomized trial.
📊 Correlative data
- IV NAD+ is used widely in clinics for fatigue, addiction recovery and post-viral states. The consistent report is that the infusion itself is unpleasant — chest tightness and nausea if run fast — and that the effect is felt immediately by some and not at all by others.
- Subcutaneous and nasal use is common in the research community with a gentler reported profile.
🧪 Theoretical / extrapolated
- NAD+ is the central redox cofactor and the substrate for the sirtuins and PARPs. Tissue NAD+ falls with age, which is the entire premise.
- The unresolved mechanistic question is whether the intact molecule enters cells at all. NAD+ is large and charged; a good deal of evidence suggests it is degraded extracellularly to nicotinamide and re-synthesized inside — which, if true, means direct administration is an expensive route to a cheaper precursor.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What NAD+ actually does
The single most important fact about NAD+ is one nobody selling an infusion says out loud: the intact molecule does not cross the plasma membrane. NAD+ is a dinucleotide — 663 Da, carrying two phosphate groups, so it is a polyanion at blood pH. A doubly charged, highly hydrophilic 663 Da molecule does not diffuse through a lipid bilayer, and no dedicated plasma-membrane NAD+ importer has been established in human cells. Whatever an infusion does, it does not do it by putting NAD+ inside your cells the way the picture on the clinic wall suggests.
What actually happens to infused NAD+ is enzymatic dismantling. Extracellular NAD+ meets a family of ectoenzymes that exist precisely to consume it. CD38 is the dominant one: a membrane NAD+ glycohydrolase that cleaves the nicotinamide-ribose bond and releases free nicotinamide plus ADP-ribose Zeidler 2022. CD73 and other ectonucleotidases strip phosphates from the fragments. The products — nicotinamide, nicotinamide riboside, ribose — can enter cells, and are then rebuilt into NAD+ through the salvage pathway by NAMPT and NMNAT. So an NAD+ infusion is, mechanistically, an expensive nicotinamide infusion delivered through an enzymatic gauntlet.
That reframes the whole compound, and it reframes the declining-NAD+ story too. The reason tissue NAD+ falls with age is at least as much about consumption as about supply: CD38 expression rises with age and with inflammation, and CD38 is described in the literature as an NAD sink Zeidler 2022. If the tap is fine and the drain is open, adding water is the less efficient of the two available moves — and the experiment that tests it exists. Peclat 2022 gave the CD38 inhibitor 78c to mice in a chronological aging model and reported increased lifespan and healthspan. That is a lifespan result from closing the drain, and there is no comparable lifespan result from opening the tap.
And the supply side is less limited than the marketing assumes. Zeidler 2022 traced where tissue nicotinamide actually comes from and found that endothelial and immune cells generate most of it endogenously rather than it arriving from the diet. A pool that is largely self-supplied is not a pool that a bolus obviously improves.
Cantó 2022 makes the related point about the precursors themselves — its title calls their redundancy questionable — and the practical version of that argument is on this page: the route matters less than the enzymes waiting at the end of it.
Cell, rodent, human — and where it stops
Step one, the biochemistry, which is settled. CD38 hydrolyzes NAD+ to nicotinamide and ADP-ribose; the salvage pathway rebuilds NAD+ from nicotinamide via NAMPT. None of this is controversial and none of it is in dispute Zeidler 2022.
Step two, in rodents, where the strongest result is about the drain and not the supply. Peclat 2022: CD38 inhibition with 78c extended lifespan and healthspan in chronologically aged mice. Zeidler 2022: tissue nicotinamide is mostly locally generated. Both are mechanism-level rodent work, and both point away from bolus supplementation as the efficient intervention.
Step three, in humans, and here is the honest position. Radenkovic 2020 surveyed the clinical evidence for targeting NAD therapeutically and the picture it describes is early: small trials, mostly with oral precursors, mostly with a biochemical endpoint rather than a clinical one. The best-characterized human data belong to nicotinamide riboside — blood NAD+ rises reliably Martens 2018, and a randomized phase 1 in Parkinson's disease reported target engagement in brain Brakedal 2022. Neither of those studies used intravenous NAD+.
The obstacle, stated exactly. For the product this page is about — NAD+ given intravenously or subcutaneously — there is no randomized controlled trial with a clinical endpoint. What exists is small uncontrolled reports and clinic experience. The gap between "NAD+ biology is important" and "an NAD+ infusion helps a person" is the entire translation step, and it has not been made.
The second obstacle is measurement. There is no ordinary clinical assay for tissue NAD+. Whole-blood NAD+ can be measured in a research setting; what it says about NAD+ in a neuron or a myocyte is an open question, because blood NAD+ sits overwhelmingly in red cells. So even a well-designed infusion trial has a hard time saying whether it hit its target.
NAD+ pharmacokinetics — how much of it actually gets in
The card says under a minute intravenously. That is not a half-life in the useful sense, and the arithmetic behind it is the most informative thing on this page.
What degrades it. Not a peptidase and not a cytochrome. NAD+ is destroyed by glycohydrolases — CD38 above all, plus CD157 and the ectonucleotidase chain — sitting on the outer face of endothelial and immune cells, which is exactly the surface an intravenous infusion is washed across Zeidler 2022. This is enzymatic hydrolysis at the vessel wall, so the clearance is proportional to how much CD38 the person expresses, and CD38 expression rises with age and inflammation. The people the infusion is marketed to are, mechanistically, the people who should clear it fastest.
The oral barrier, which is why the oral capsule on this page is a different product from the vial. Oral NAD+ meets pancreatic and brush-border enzymes and is dismantled before absorption; what crosses the enterocyte is nicotinamide and nicotinamide riboside, not NAD+. An oral NAD+ product is a precursor product wearing the name of the coenzyme, and Cantó 2022 is the paper that treats that distinction seriously.
The arithmetic, done twice. A 500 mg NAD+ dose is about 750 µmol; distributed instantly into 5 L of plasma that is roughly 150 µmol/L, which is a large multiple of the normal circulating concentration — and it is that steep gradient, not the dose, that drives the flushing, nausea and chest tightness people report when an infusion is run fast. With a plasma half-life under a minute, a 2-hour infusion is not a 2-hour exposure to NAD+; it is 120 minutes of continuous conversion to nicotinamide at the endothelial surface. The slow drip is not a comfort measure; it is the only way to deliver a molecule that is destroyed as fast as it arrives.
The downstream metabolites are the part with real duration: nicotinamide has a half-life measured in hours and is what the tissue salvage pathway actually consumes Zeidler 2022. The card's "hours as precursor metabolites" is correct, and it is describing a different molecule from the one in the bag.
What would have to be true, and how you would know it was not
Three predictions, and the first is the one that should be on every clinic's intake form and is on none of them.
1. Homocysteine should be watched, because clearing a nicotinamide load costs methyl groups. Excess nicotinamide is disposed of by nicotinamide N-methyltransferase, which takes a methyl group from S-adenosylmethionine and leaves S-adenosylhomocysteine — which hydrolyzes to homocysteine. Repeated large NAD+ or nicotinamide loads are therefore a methyl sink, and the prediction is a rising homocysteine in anyone whose folate and vitamin B12 status is marginal. Draw all three before a course of infusions and again at 8–12 weeks. This is the prediction that cuts against the product, it is cheap, and it is falsifiable in either direction.
2. If the fatigue benefit is a real metabolic effect rather than an infusion-day effect, it should outlast the appointment. The plasma half-life is under a minute and the metabolites are gone within a day. Any benefit lasting weeks has to be a downstream change in the cell, not residual drug. The test is a symptom diary kept across a gap between infusions rather than on infusion day, and a hs-CRP drawn at both ends: a real change in inflammatory tone should show, and if it does not, the honest reading is that the effect is on the day and about the day.
3. A CMP is the safety half and is the thing nobody orders. Infusions are given in non-clinical settings at doses far above anything a diet provides, and high-dose nicotinamide has a known hepatic signal at gram-level chronic exposure. A CMP before a course and after it is the minimum, and if a person is running repeated infusions it should be repeated too.
What nobody has tested yet
Four things that have never been tested about intravenous NAD+ and plainly could be.
Nobody has compared an NAD+ infusion against an equimolar nicotinamide infusion. If the mechanism above is right — CD38 dismantles NAD+ at the vessel wall and the cell takes up the pieces Zeidler 2022 — then the two arms should be indistinguishable, and nicotinamide costs a fraction as much. That is a two-arm study with a biochemical endpoint, and it would either justify the price of the vial or end the argument.
Nobody has measured CD38 activity as a predictor of who responds. The mechanism says clearance depends on CD38 density, which varies several-fold between people and rises with age. Nobody has stratified an infusion cohort by leukocyte CD38 expression, and it is measurable by ordinary flow cytometry.
Nobody has measured homocysteine across a course of infusions. The methyl-sink chemistry above is textbook, the measurement is on every standard panel, and the intersection is empty.
Nobody has tested a CD38 inhibitor in a person for this purpose. The strongest NAD+ lifespan result in any species came from inhibiting the enzyme rather than supplying the substrate Peclat 2022. Apigenin and quercetin are both reported CD38 inhibitors, both are sold on this site, and no one has run the obvious human study of what either does to whole-blood NAD+. That study is cheap, and it is the one that would tell you whether the drain matters more than the tap in a human.
NAD+ — its own safety story, not its class's
The class block above is written for longevity compounds broadly. The risks here are specific and mostly procedural.
The infusion reaction is a concentration-gradient phenomenon, not an allergy. Flushing, nausea, abdominal cramping and chest tightness during a fast NAD+ drip track the rate, not the total dose, and they settle when the rate is reduced. Understanding it as a gradient effect is the difference between slowing the drip and stopping the course.
The real hazard of an infusion is the infusion. Intravenous access placed outside a clinical setting carries the risks that come with intravenous access — phlebitis, extravasation, bloodstream infection — and those risks are unrelated to the molecule and larger than anything attributable to it. This is the one place where the delivery route, not the pharmacology, is the safety story.
The chronic methyl load is the mechanistic risk. See the prediction above. It is theoretical in the sense that nobody has measured it on this product, and it is not speculative in the sense that the enzymology is not in doubt.
The honest bottom line on evidence. Radenkovic 2020 is the review to read, and what it describes is a field with real biology and thin clinical data. The compound is not dangerous in any way the record shows. It is unproven in the specific form sold here, which is a different sentence, and the two get conflated on every clinic website that sells it.
Sources read for this page
- Radenkovic D, et al. Clinical Evidence for Targeting NAD Therapeutically. Pharmaceuticals (Basel) 2020 · PMID 32942582
- Zeidler JD, et al. The CD38 glycohydrolase and the NAD sink: implications for pathological conditions. American Journal of Physiology - Cell Physiology 2022 · PMID 35138178
- Zeidler JD, et al. Endogenous metabolism in endothelial and immune cells generates most of the tissue vitamin B3 (nicotinamide). iScience 2022 · PMID 36388973
- Peclat TR, et al. CD38 inhibitor 78c increases mice lifespan and healthspan in a model of chronological aging. Aging Cell 2022 · PMID 35263032
- Cantó C. NAD+ Precursors: A Questionable Redundancy. Metabolites 2022 · PMID 35888754
NAD+ — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These act on mitochondrial function, NAD+ availability, sirtuin signaling or cellular clearance. The honest prediction is that acute harm is unlikely and the interesting risks are theoretical and long-range — which is a different shape of risk, not an absence of one.
- Growth and clearance signals cut both ways. Anything that improves the efficiency of cell survival is also improving it for cells you would rather not keep. Anything that pushes clearance hard is doing so indiscriminately.
- The near-term, practical ones: NAD+ precursors and infusions commonly cause flushing and a strong sensation if pushed fast, and several compounds in this class are stimulating enough to disrupt sleep.
What has actually been reported
- Generally well tolerated at studied doses. NAD+ infusion discomfort is rate-dependent and resolves by slowing down.
- The human evidence is mostly short trials with surrogate endpoints — a marker moved, not a life changed. That is worth knowing before you build a decade-long habit on it.
How to reduce the risk
Same mechanism as the prediction.
- Slow the infusion rate. Almost all NAD+ discomfort is rate, not dose. There is no prize for finishing quickly.
- Dose earlier in the day. Several of these are subtly stimulating, and sleep is where most of the repair you are paying for happens.
- Pick an endpoint you can actually measure, and take the baseline before you start. This is the class most prone to spending years on something with no way of knowing whether it did anything.
- Fix the basics first. Sleep, training and bloodwork move the same markers further than anything on this list, and they are free. A longevity compound stacked on four hours of sleep is a rounding error.
What it does to your bloodwork
A fact about the assay.
- There is no NAD+ assay worth ordering clinically. Judge this class on downstream markers — inflammatory markers, lipids, fasting glucose, and whatever your baseline panel showed as out of range.
Don't run this if
- Active malignancy, for the survival-signaling reasoning above.
- Pregnancy — uncharacterized.
The honest unknown
- Whether any of it extends healthspan in humans. Every honest person in this field is running on mechanism and animal data, and this catalog should say so rather than imply otherwise.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
NAD+ — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What NAD+ moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside NAD+
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation, which is what most NAD claims route through |
| HbA1c (Hemoglobin A1c) | Metabolic health, the other half |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
NAD+ — frequently asked questions
What is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell uses for energy production and for fueling repair enzymes (sirtuins and PARPs). Its levels decline with age, which is why it's central to longevity research.
How does boosting NAD+ work?
Restoring NAD+ — directly or via precursors like NMN/NR — reactivates sirtuins and DNA-repair enzymes, improving mitochondrial function and genomic stability in research models.
Does NAD+ actually slow aging?
In animals, NAD+/precursor supplementation increased lifespan and healthspan. In humans, precursors reliably raise NAD+ and improve some markers, but whether it extends human healthspan is still being studied.
What's the difference between IV, injectable, and oral NAD+?
Oral precursors (NMN, NR) are convenient and well-studied; IV NAD+ delivers large amounts directly over hours in a clinic; subcutaneous injection is a faster at-home-style route. Direct NAD+ causes more acute side effects than oral precursors.
How is NAD+ dosed?
IV references commonly cite 500–1,500 mg per session; oral NMN/NR is hundreds of mg to ~1 g daily; subq references smaller amounts reconstituted with bacteriostatic water (see calculator). IV/injectable use should be medically supervised. This is educational, not dosing advice.
Are there side effects to NAD+?
Oral precursors are well tolerated. Direct IV/injectable NAD+ can cause chest tightness, flushing, headache and nausea — especially if infused quickly — which is why it's supervised.
References & further reading
- NAD+ and sirtuins in aging/longevity control (PMC review)
- Targeting NAD+ in metabolic disease — insights (PMC)
- NMN supplementation and aerobic capacity — randomized study (PMC)
NAD+ inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What NAD+ is used for
NAD+ appears under 5 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
NAD+ is the nad+ arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.